Compare · AZN vs IRWD
AZN vs IRWD
Side-by-side comparison of AstraZeneca PLC (AZN) and Ironwood Pharmaceuticals Inc. (IRWD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and IRWD operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $262.52B, about 412.1x IRWD ($637.1M).
- Over the past year, AZN is down 10.5% and IRWD is up 387.0% - IRWD leads by 397.4 points.
- AZN has been more active in the news (15 items in the past 4 weeks vs 2 for IRWD).
- AZN has more recent analyst coverage (25 ratings vs 14 for IRWD).
- Company
- AstraZeneca PLC
- Ironwood Pharmaceuticals Inc.
- Price
- $168.53-0.43%
- $3.87-0.26%
- Market cap
- $262.52B
- $637.1M
- 1M return
- -5.70%
- +5.45%
- 1Y return
- -10.45%
- +386.98%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2010
- News (4w)
- 15
- 2
- Recent ratings
- 25
- 14
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist, which is in pre-clinical development for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca downgraded by HSBC Securities
- SEC Form 6-K filed by AstraZeneca PLC
- Officer Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,265 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
- Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 11-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest IRWD
- Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients
- PFO & PAO Silver Ronald sold $578,063 worth of shares (127,890 units at $4.52) as part of a pre-agreed trading plan, decreasing direct ownership by 29% to 313,680 units (SEC Form 4)
- Ironwood Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Shepard Jay was granted 63,481 shares, increasing direct ownership by 37% to 235,036 units (SEC Form 4)
- Director Kessler Marla L was granted 63,481 shares, increasing direct ownership by 38% to 229,364 units (SEC Form 4)
- Director Currie Mark G was granted 63,481 shares, increasing direct ownership by 10% to 676,900 units (SEC Form 4)
- Director Duane Jon R was granted 63,481 shares, increasing direct ownership by 33% to 253,820 units (SEC Form 4)
- Director Denner Alexander J was granted 67,546 shares, increasing direct ownership by 26% to 323,855 units (SEC Form 4)
- Director Mchugh Julie sold $80,460 worth of shares (21,571 units at $3.73) as part of a pre-agreed trading plan and was granted 63,481 shares, increasing direct ownership by 20% to 250,749 units (SEC Form 4)
- Director Moukheibir Catherine was granted 63,481 shares, increasing direct ownership by 54% to 181,425 units (SEC Form 4)